Featured essay
Biologics CDMO capacity is expanding, but not fast enough for the reshuffled supply chain in 2026Biologics contract manufacturers are investing at record pace—mammalian cell culture capacity is projected to grow 40.4% over five years—yet the market remains tight. The tension is not just volume. The BIOSECURE Act is forcing sponsors away from Chinese CDMOs into a narrower…
Read full essay